All In Biotech

Drug Trial Radar · NCT04338022

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 1)

Last checked: Nov 20, 2026Latest source record: Jun 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,124 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,124

Actual

Start

Jun 12, 2020

Primary completion

Oct 2, 2023

Study completion Mar 8, 2024

Sponsor

Sponsor type
Industry
Collaborators
EMD Serono Research & Development Institute, Inc.
First posted
Apr 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • TeriflunomideDrug

    Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period and followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in open label extension (OLE) period.

  • EvobrutinibDrug

    Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period and followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in open label extension (OLE) period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)Time frame: From baseline to 172 weeks
  2. Open Label Extension (OLE) Period: Number of Participants With Adverse Events (AEs) and Serious AEsTime frame: From OLE Baseline (DBTP Week 96) to OLE Week 52

Locations

279 sites in 31 countries. Site status is shown where the registry gives one.

  • Research Site 629

    Mobile, Alabama

  • Research Site 614

    Phoenix, Arizona

  • Research Site 677

    Phoenix, Arizona

  • Research Site 642

    Long Beach, California

  • Research Site 644

    Pasadena, California

  • Research Site 672

    San Diego, California

  • Research Site 634

    Stamford, Connecticut

  • Research Site 656

    Washington D.C., District of Columbia

  • Research Site 616

    Boca Raton, Florida

  • Research Site 625

    Maitland, Florida

  • Research Site 617

    Miami, Florida

  • Research Site 643

    Ormond Beach, Florida

  • Research site 645

    St. Petersburg, Florida

  • Research Site 652

    Tallahassee, Florida

  • Research Site 621

    Elk Grove Village, Illinois

  • Research Site 649

    Northbrook, Illinois

  • Research Site 675

    Peoria, Illinois

  • Research Site 628

    Rolling Meadows, Illinois

  • Research Site 624

    Indianapolis, Indiana

  • Research Site 632

    Kansas City, Kansas

  • Research Site 653

    New Orleans, Louisiana

  • Research Site 623

    Baltimore, Maryland

  • Research Site 633

    Boston, Massachusetts

  • Research Site 639

    Foxborough, Massachusetts

  • Research Site 635

    Lawrence, Massachusetts

  • Research Site 636

    Worcester, Massachusetts

  • Research Site 613

    Detroit, Michigan

  • Research Site 612

    Farmington Hills, Michigan

  • Research Site 638

    St Louis, Missouri

  • Research Site 664

    St Louis, Missouri

  • Research Site 668

    Omaha, Nebraska

  • Research Site 626

    Las Vegas, Nevada

  • Research Site 667

    Audubon, New Jersey

  • Research Site 620

    Patchogue, New York

  • Research Site 663

    Akron, Ohio

  • Research Site 630

    Toledo, Ohio

  • Research Site 611

    Oklahoma City, Oklahoma

  • Research Site 641

    Oklahoma City, Oklahoma

  • Research Site 615

    Springfield, Oregon

  • Research Site 647

    Willow Grove, Pennsylvania

Showing 40 of 279 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.